Background and Aims: Mps One Binder Kinase Activator(MOB) 1A/1B, core components of the Hippo pathway, have been recognized in various human tumors. However, the roles of MOB1 in lung adenocarcinoma are largely unknown. We investigated the relationship between MOB1 expression and prognosis of lung adenocarcinoma patients.
1A/1B, core components of the Hippo pathway, have been recognized in various human tumors. However, the roles of MOB1 in lung adenocarcinoma are largely unknown. We investigated the relationship between MOB1 expression and prognosis of lung adenocarcinoma patients.
Methods: MOB1 expression was immunohistochemically studied in 208 surgically resected lung adenocarcinoma. The association between expression of MOB1 and clinicopathological parameters was evaluated.
Results: MOB1 expression was significantly associated with vascular invasion (P = 0.0005). However, P-TNM stage was not significantly associated with MOB1 expression (P = 0.3151). In MOB1 high expression group, the disease-free survival was significantly shortened compared to the MOB1 low group (P = 0.0161), but no significant difference was observed in the overall survival.
Conclusion: This study suggests that MOB1 expression in lung adenocarcinoma is a risk factor for early recurrence, and further studies are required on the effect of MOB1 on tumor growth or vascular invasion. Background and Aims: Using chest computed tomographic (CT) images showed an improved detection rate and survival of early-stage lung cancers. Although chest CT scan suffers from high cost also lack of sensitivity and specificity. Biomarkers for lung cancer have the potential to improve early detection beyond the use of CT scans. This study investigated the process of cancer immunoediting involved in lung cancer diagnosis.
Methods: Patients with pulmonary nodules detected by chest CT scan was selected to enroll the study. Peripheral blood samples were collected for analysis of T cell population. T cells subtypes including CD3, CD4, CD8, CD27, CD28, CD45, CD45RA, CD57, CCR7 and PD1 were counted by cytoflex flow cytometer (Beckman Coulter) before surgical resection or biopsy.
Definite diagnosis was made based on pathological examination of surgical specimens. Patients' basic data were retrieved from electronic medical records and analyzed for age, gender, histology type and cancer staging.
Results: The differences between lung cancer patients (n = 27) and benign lesions (n = 26), and the changes in the frequency of T-cell subpopulations among lung cancer patients corresponded to those seen in immunosenescence: lower proportions of CD8+CD27+ cells consisting of naïve and central memory cells according to lung cancer clinical stage compared to patients without malignancy. In addition, higher proportion of CD8+PD1+ cells among the advanced stage lung cancer patients was detected. Also observed was a tendency of higher CD8+PD1+ expression cells in squamous cell lung cancer.
Conclusion:
Immunosenescence was present at the development of lung cancer. It appeared to be pronounced in patients with advanced stage of lung cancer. Cancer immunoediting will provide early-stage cancer detection and further therapeutic strategies. covery and validation datasets, respectively. We selected 8587 SNPs in 83 genes in the signaling and extracted genotyping data from the PLCO. We performed Cox proportional hazards regression analysis to evaluate associations between the SNPs and survival and validated the significant SNPs, and analyzed their functional relevance.
AO042 GENETIC VARIANTS IN THE C-MYB SIGNALING PATHWAY GENES PREDICT SURVIVAL OF NON-SMALL CELL LUNG CANCER PATIENTS IN THE PLCO CANCER
Results: rs11606640 ETS1 GA+AA and rs62053220 ZFHX3 CG+GG genotypes of two validated SNPs predicted a better overall survival (OS) (P = 0.004 and 0.001, respectively). The number of their combined genotypes predicted a better OS in a multivariable Cox model. Stratified analysis showed that patients with a high-score protective genotypes exhibited significantly favorable survival in subgroups of current smoker, adenocarcinoma, IIIB-IV tumor stage, and without surgery (all P < 0.05). ETS1 and ZFHX3 mRNA expression levels were significantly lower in lung cancer tissues than in normal tissues (P < 0.05). The TCGA-based expression quantitative trait loci analysis showed that ETS1 rs11606640 genotypes were significantly associated with their corresponding mRNA expression levels in lung cancer tissues in an additive model and a recessive model (P = 0.045 and 0.042, respectively). ZFHX3
Respirology ( 
